The ATB-Raisin antibiotic (ATB) usage monitoring system contributes to the appropriate use of antibiotics. Its objectives are to enable each healthcare facility (HCF) to describe and analyze its antibiotic usage in comparison with a comparable group and to cross-reference this data with bacterial resistance data. Systemic ATBs in class J01 of the Anatomical Therapeutic Chemical (ATC) classification, rifampicin, oral imidazoles and fidaxomicin, as well as systemic antifungals in class J02, dispensed during inpatient stays, were expressed in terms of defined daily doses (DDD) and reported according to national and World Health Organization recommendations (ATC-DDD system, 2014). Resistance data were collected for seven bacteria/antibiotic pairs. The 1,484 participating healthcare facilities in 2014 accounted for 70% of inpatient days and had consumed 375 DDDs per 1,000 inpatient days (ID). The most commonly used antibiotics were the amoxicillin-clavulanic acid combination (30%), amoxicillin (18%), and ceftriaxone (6%). Median antibiotic consumption ranged from 55 DDD/1,000 HD in psychiatric hospitals to 699 in military training hospitals. Variations were observed across specialties, ranging from 60 DDD/1,000 HD in psychiatry to 1,513 in intensive care. In the 621 healthcare facilities that participated every year since 2009, consumption decreased between 2013 and 2014 (-1.8%), whereas it had increased by 3.3% between 2009 and 2013. Resistance data were consistent with those from specific networks. Antifungal consumption was higher in hematology (330 DDD/1,000 patient-days) than in intensive care (153 DDD/1,000 patient-days). Network-based surveillance allows each healthcare facility to assess its position relative to others, exchange information on practices and organizational structures, and track evolving trends. The analysis of antibiotic consumption should be supplemented by an evaluation of practices and the monitoring of indicators reflecting the quality of prescribing.